Global Information
회사소개 | 문의 | 비교리스트

간질환 치료제 시장 : 치료 유형, 질환 유형별(간염, 자가면역질환, 비알코올성 지방간질환 환, 암, 유전성 질환, 기타) - 세계 기회 분석 및 산업 예측(2021-2030년)

Liver Disease Treatment Market by Treatment Type and Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease, Cancer, Genetic Disorders and Others): Global Opportunity Analysis and Industry Forecast, 2021-2030

리서치사 Allied Market Research
발행일 2021년 12월 상품코드 1059608
페이지 정보 영문 254 Pages 배송안내 2-3일 (영업일 기준)
가격
US $ 4,125 ₩ 5,310,000 Excel (Data Pack) help
DRM(디지털 저작권 관리 시스템) 장착 Excel 파일로, 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 Excel파일 라이선스 소유자로 한정됩니다.
US $ 6,168 ₩ 7,940,000 PDF (Single User License + Covid impact) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 6,929 ₩ 8,919,000 PDF (5-user License) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,663 ₩ 13,726,000 PDF (Enterprise User License) help
동일 기업 내의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



간질환 치료제 시장 : 치료 유형, 질환 유형별(간염, 자가면역질환, 비알코올성 지방간질환 환, 암, 유전성 질환, 기타) - 세계 기회 분석 및 산업 예측(2021-2030년) Liver Disease Treatment Market by Treatment Type and Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease, Cancer, Genetic Disorders and Others): Global Opportunity Analysis and Industry Forecast, 2021-2030
발행일 : 2021년 12월 페이지 정보 : 영문 254 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 간질환 치료제 시장 규모는 2020년 206억 7,370만 달러에서 예측 기간 중 5.7%의 CAGR로 추이하며, 2030년에는 364억 5,570만 달러 규모로 성장할 것으로 예측됩니다.

알코올 소비량의 증가, 비만, 건강하지 못한 식생활, 스트레스의 증가에 의한 건강하지 못한 라이프스타일, 노년 인구의 증가 등이 시장 성장의 주요 요인입니다. 또한 이미징 기술의 진보, Drug Discovery의 급증, 질환의 신규 치료법, R&D 활동의 증가, 민간 및 공적 기관에 의한 연구 자금의 제공, 간질환에 관한 계발을 위한 정부의 다양한 구상도 시장 성장을 지원할 것으로 기대되고 있습니다.

세계의 간질환 치료제 시장을 조사했으며, 시장의 정의와 개요, 시장 영향요인 분석, 시장 규모의 추이·예측, 치료 유형·질환 유형·지역/주요 국가 등 각종 부문별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 개요

제3장 시장 개요

  • 시장의 정의·범위
  • 주요 조사 결과
  • Porter의 산업 분석
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 촉진요인
    • 억제요인
    • 시장 기회
  • 영향 분석
  • COVID-19의 영향 분석

제4장 간질환 치료제 시장 : 치료 유형별

  • 개요
  • 항바이러스제
  • 면역억제제
  • 백신
  • 면역글로불린
  • 코르티코스테로이드
  • 표적치료
  • 화학요법
    • 주요 시장 동향·성장요인·기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제5장 간질환 치료제 시장 : 질환 유형별

  • 개요
  • 간염
  • 자가면역질환
  • 비알코올성 지방간질환(NAFLD)
  • 유전성 질환
  • 기타
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제6장 간질환 치료제 시장 : 지역별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카·중동·아프리카
    • 주요 시장 동향·성장요인·기회
    • 간질환 치료제 시장 : 치료 유형별
    • 간질환 치료제 시장 : 질환 유형별
    • 간질환 치료제 시장 : 국가별

제7장 기업 개요

  • ABBVIE INC.
  • ABBOTT LABORATORIES
  • ASTELLAS PHARMA INC.
  • BRISTOL-MYERS SQUIBB
  • ELI LILLY AND COMPANY
  • EMERGENT BIOSOLUTIONS INC.(CANGENE BIOPHARMA)
  • F. HOFFMANN-LA ROCHE AG
  • GILEAD SCIENCES, INC.
  • MERCK & CO. INC.
  • VIATRIS INC.
KSA 22.03.08

LIST OF TABLES

  • TABLE 01.LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 02.ANTIVIRAL DRUGS MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
  • TABLE 03.IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
  • TABLE 04.VACCINES MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.IMMUNOGLOBULINS MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.CORTICOSTEROIDS MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
  • TABLE 07.TARGETED THERAPY MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
  • TABLE 08.CHEMOTHERAPY MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 10.LIVER DISEASE TREATMENT MARKET FOR HEPATITIS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.LIVER DISEASE TREATMENT MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2020-2030($MILLION)
  • TABLE 12.LIVER DISEASE TREATMENT MARKET FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), BY REGION, 2020-2030($MILLION)
  • TABLE 13.LIVER DISEASE TREATMENT MARKET FOR CANCER, BY REGION, 2020-2030($MILLION)
  • TABLE 14.LIVER DISEASE TREATMENT MARKET FOR GENETIC DISORDERS, BY REGION, 2020-2030($MILLION)
  • TABLE 15.LIVER DISEASE TREATMENT MARKET FOR OTHERS, BY REGION, 2020-2030($MILLION)
  • TABLE 16.LIVER DISEASE TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 17.NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 18.NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 19.NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 20.U.S. LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 21.U.S. LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 22.CANADA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 23.CANADA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 24.MEXICO LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 25.MEXICO LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 26.EUROPE LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 27.EUROPE LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 28.EUROPE LIVER DISEASE TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 29.GERMANY LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 30.GERMANY LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 31.FRANCE LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 32.FRANCE LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 33.UK LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 34.UK LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 35.ITALY LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 36.ITALY LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 37.SPAIN LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 38.SPAIN LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 39.REST OF EUROPE LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 40.REST OF EUROPE LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 41.ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 42.ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 43.ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 44.JAPAN LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 45.JAPAN LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 46.CHINA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 47.CHINA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 48.AUSTRALIA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 49.AUSTRALIA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 50.INDIA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 51.INDIA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 52.SOUTH KOREA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 53.SOUTH KOREA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 54.REST OF ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 55.REST OF ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 56.LAMEA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 57.LAMEA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 58.LAMEA LIVER DISEASE TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 59.BRAZIL LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 60.BRAZIL LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 61.SAUDI ARABIA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 62.SAUDI ARABIA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 63.SOUTH AFRICA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 64.SOUTH AFRICA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 65.REST OF LAMEA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 66.REST OF LAMEA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 67.ABBVIE: COMPANY SNAPSHOT
  • TABLE 68.ABBVIE: PRODUCT SEGMENTS
  • TABLE 69.ABBVIE: PRODUCT PORTFOLIO
  • TABLE 70.ABBVIE: KEY DEVELOPMENTS
  • TABLE 71.ABBOTT: COMPANY SNAPSHOT
  • TABLE 72.ABBOTT: OPERATING SEGMENTS
  • TABLE 73.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 74.ASTELLAS: COMPANY SNAPSHOT
  • TABLE 75.ASTELLAS: OPERATING SEGMENTS
  • TABLE 76.ASTELLAS: PRODUCT PORTFOLIO
  • TABLE 77.BRISTOL: COMPANY SNAPSHOT
  • TABLE 78.BRISTOL: PRODUCT SEGMENTS
  • TABLE 79.BRISTOL: PRODUCT PORTFOLIO
  • TABLE 80.LILLY: COMPANY SNAPSHOT
  • TABLE 81.LILLY: OPERATING SEGMENTS
  • TABLE 82.LILLY: PRODUCT PORTFOLIO
  • TABLE 83.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84.EMERGENT SOLUTIONS: COMPANY SNAPSHOT
  • TABLE 85.EMERGENT SOLUTIONS: OPERATING SEGMENTS
  • TABLE 86.EMERGENT SOLUTIONS: PRODUCT PORTFOLIO
  • TABLE 87.ROCHE: COMPANY SNAPSHOT
  • TABLE 88.ROCHE: PRODUCT SEGMENTS
  • TABLE 89.ROCHE: PRODUCT PORTFOLIO
  • TABLE 90.ROCHE: KEY DEVELOPMENTS
  • TABLE 91.GILEAD: COMPANY SNAPSHOT
  • TABLE 92.GILEAD: OERATING SEGMENT
  • TABLE 93.GILEAD: PRODUCT PORTFOLIO
  • TABLE 94.MERCK: COMPANY SNAPSHOT
  • TABLE 95.MERCK: OPERATING SEGMENTS
  • TABLE 96.MERCK: PRODUCT PORTFOLIO
  • TABLE 97.VIATRIS: COMPANY SNAPSHOT
  • TABLE 98.VIATRIS: OPERATING BUSINESS SEGMENTS
  • TABLE 99.VIATRIS: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.GLOBAL LIVER DISEASE TREATMENT MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
  • FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.HIGH BARGAINING POWER OF BUYERS
  • FIGURE 08.HIGH THREAT OF SUBSTITUTES
  • FIGURE 09.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 10.HIGH INTENSITY OF RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2020
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR ANTIVIRAL DRUGS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 14.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR IMMUNOSUPPRESSANTS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 15.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR VACCINES, BY COUNTRY, 2020-2030 (%)
  • FIGURE 16.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 17.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR TARGETED THERAPY, BY COUNTRY, 2020-2030 (%)
  • FIGURE 19.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2020-2030 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR HEPATITIS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 21.COMPARATIVE ANALYSIS OF FOR LIVER DISEASE TREATMENT MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2020-2030 (%)
  • FIGURE 22.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), BY COUNTRY, 2020-2030 (%)
  • FIGURE 23.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR CANCER, BY COUNTRY, 2020-2030 (%)
  • FIGURE 24.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 25.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 26.ABBVIE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 27.ABBVIE: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 28.ABBOTT: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 29.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 30.ABBOTT: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 31.ASTELLAS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 32.ASTELLAS: REVENUE SHARE, BY SEGMENTS, 2020 (%)
  • FIGURE 33.ASTELLAS: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 34.BRISTOL: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 35.BRISTOL: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 36.LILLY: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 37.LILLY: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 38.EMERGENT SOLUTIONS: NET SALES, 2019-2020 ($MILLION)
  • FIGURE 39.EMERGENT SOLUTIONS: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 40.EMERGENT SOLUTIONS: REVENUE SHARE, BY REGION, 2020(%)
  • FIGURE 41.ROCHE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 42.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 43.ROCHE: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 44.GILEAD: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 45.MERCK: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 46.MERCK: REVENUE SHARE, BY SEGMENTS, 2020 (%)
  • FIGURE 47.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 48.VIATRIS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 49.VIATRIS: REVENUE SHARE, BY REGION, 2020 (%)

The global liver disease treatment market was valued at $20,673.70 million in 2020, and is estimated to reach $36,455.70 million by 2030, growing at a CAGR of 5.7% from 2021 to 2030. The liver is a vital organ of the body and has more than 500 functions and has primary functions such as bile production & excretion, excretion of bilirubin, cholesterol, hormones, and drugs. It fights infection, eliminates toxins that are blood detoxification and purification. Liver disease comprises a range of complex conditions that affect the liver. Liver dysfunction can be fatal, and can cause a variety of acute and chronic disorders, including hepatitis A, hepatitis B, hepatitis C, non-alcoholic fatty liver disease, liver cancer, bile duct cancer, liver cell adenoma, and liver cirrhosis. Liver diseases are caused due to inheritance, such as hemochromatosis, hyperoxaluria, and Wilson's disease.

Medical care given to a patient suffering from liver diseases is termed as liver disease treatment. Furthermore, the treatment includes use of various drugs for different types of liver conditions. For instance, hepatitis B is a liver disease caused by a virus called hepatitis B virus (HBV). This condition is treated using antiviral drugs and can also be prevented by use of vaccines. Furthermore, other drugs that are used in treatment of hepatitis include immunoglobulin. Similarly, liver cancer is treated by using chemotherapy drugs and targeted therapy. In addition, some autoimmune liver related disorders are treated with the use of corticosteroids. Furthermore, liver associated conditions require liver transplant in many cases, where immunosuppressant drugs are used to prevent organ rejection.

Swelling in the abdomen and legs, easy bruising, changes in the color of faeces & urine, and jaundice, or yellowing of the skin and eyes, are all common symptoms of liver disease. Imaging and liver function testing can both detect liver damage and aid in the diagnosis of liver diseases. The liver disease treatments majorly comprise of immunosuppressant's, chemotherapy drugs, targeted therapy, vaccines, antiviral drugs, immunoglobulins, and corticosteroids. In addition, these products are used to cure a range of liver diseases, which include hepatitis, autoimmune diseases, non-alcoholic fatty liver, and genetic disorders

Increase in alcohol consumption, obesity, unhealthy diets, unhealthy lifestyle due to increase stress, and rise in geriatric population are the major factors that drive the growth of the market. Rise in the consumption of alcohol is one of the major factors that leads to liver disorders. Alcohol alters the chemicals that break down scar tissue and eliminate it. This means that scar tissue accumulates in the liver and normal healthy cells are replaced by scar tissue. Thus, the liver is unable to function properly and may fail, resulting in death. Alcohol-related liver disease (ARLD) include alcoholic fatty liver disease, acute alcoholic hepatitis and alcoholic cirrhosis.

For instance, according to the National Center for Drug Abuse Statistics 2021, there were about 95.2 thousand alcohol-related deaths among which 31.08% were due to liver diseases. Alcoholic liver disease is the leading killer, which causes 19.1% of all alcohol-related deaths. Thus, such high mortality can be prevented by appropriate liver treatment at the right time, and thus boosts the growth of the market.

In addition, overweight and obesity is another major factor driven by rise in consumption of carbohydrate-based foods, packaged foods, poor eating habits, and unhealthy lifestyle among young generation as well adults thus leading to weight gain and further obesity. According to the World Health Organization (WHO), the majority of the world's population lives in countries where obesity and overweight people kills more people than persons who are underweight.

Furthermore, according to the World Obesity Federation that by 2025, approximately 2.7 billion adults would be overweight, over 1 billion will be obese, and 177 million adults will be extremely obese, if current trends continue. Fat accumulates in the liver as a result of being overweight or obese. This leads to chronic inflammation and scarring of the liver also known as cirrhosis. Thus, surge in obesity population is expected to boost the liver disease treatment market.

Moreover, increase in population especially the geriatric leads to rise in chronic diseases and may lead to liver dysfunction. Surge in diabetes, cardiovascular diseases, metabolic syndromes further lead to liver disorders. For instance, in March 2020, the Drug Controller General of India (DCGI) has approved Zydus Cadila's new drug application for saroglitazar, which is used to treat non-cirrhotic non-alcoholic steatohepatitis (NASH). NASH ranks as one of the major causes of cirrhosis, behind hepatitis C and alcoholic liver disease. In advanced cirrhosis with liver failure, liver transplantation is the only treatment option. Thus, approval of such drugs and various government initiatives for liver disease awareness are anticipated to further drive the growth of the liver disease treatment market.

Increase in the liver disease treatment is majorly due to technological advancements in imaging, surge in drug discovery, novel treatments for the diseases, increase in R & D activities, and research funding by both private and public organizations. In addition, various government initiatives for awareness regarding the liver disorders is expected to boost the market growth.

The global liver disease treatment market is segmented into treatment type, disease type, and region. On the basis of treatment, the market is segregated into antiviral drugs, immunosuppressant's, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy drugs. By disease type, it is categorized into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others (congenital hepatic fibrosis and biliary atresia).

The major players profiled in the report are AbbVie Inc., Abbott Laboratories, Astellas Pharma Inc., Bristol Myers Squibb, Eli Lilly and Company, F. Hoffman-LA Roche, Emergent BioSolutions (Cangene bioPharma), Gilead Sciences, Inc., Merck & Co., Inc. (Merck Sharp & Dohme Corp.), and Viatris Inc.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global liver disease treatment market to identify the prevailing opportunities.
  • This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Region- & country-wise analysis is provided to understand the market trends and dynamics.

KEY MARKET SEGMENTS

By Treatment Type

  • Antiviral Drugs
  • Immunosuppressant's
  • Vaccines
  • Immunoglobulins
  • Corticosteroids
  • Targeted Therapy
  • Chemotherapy

By Disease Type

  • Hepatitis
  • Autoimmune Diseases
  • Non-Alcoholic Fatty Liver Disease (NAFLD)
  • Cancer
  • Genetic Disorders
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • AbbVie Inc.
  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Bristol Myers Squibb
  • Eli Lilly and Company
  • F. Hoffman-LA Roche
  • Emergent BioSolutions (Cangene bioPharma)
  • Gilead Sciences, Inc.,
  • Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
  • Viatris Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profile in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Rise in incidence of liver diseases
      • 3.5.1.2.Increased alcohol consumption and poor dietary habits
      • 3.5.1.3.Surge in geriatric population
      • 3.5.1.4.Increase in government and nongovernment awareness programs
    • 3.5.2.Restraints
      • 3.5.2.1.Stringent regulatory approvals related to liver disease treatment drugs and vaccines
      • 3.5.2.2.Resistance to antiviral drugs used in treatment of hepatitis B and hepatitis C
    • 3.5.3.Opportunity
      • 3.5.3.1.Presence of strong pipeline products
  • 3.6.Impact analysis
  • 3.7.Impact analysis of COVID-19 on the liver disease treatment market

CHAPTER 4:LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Antiviral drugs
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Immunosuppressants
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Vaccines
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
  • 4.5.Immunoglobulins
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country
  • 4.6.Corticosteroids
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast, by region
    • 4.6.3.Market analysis, by country
  • 4.7.Targeted therapy
    • 4.7.1.Key market trends, growth factors, and opportunities
    • 4.7.2.Market size and forecast, by region
    • 4.7.3.Market analysis, by country
  • 4.8.Chemotherapy
    • 4.8.1.Key market trends, growth factors, and opportunities
    • 4.8.2.Market size and forecast, by region
    • 4.8.3.Market analysis, by country

CHAPTER 5:LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Hepatitis
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Autoimmune diseases
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country
  • 5.4.Non-alcoholic fatty liver disease (NAFLD)
    • 5.4.1.Market size and forecast, by region
    • 5.4.2.Market analysis, by country
  • 5.5.Cancer
    • 5.5.1.Market size and forecast, by region
    • 5.5.2.Market analysis, by country
  • 5.6.Genetic disorders
    • 5.6.1.Market size and forecast, by region
    • 5.6.2.Market analysis, by country
  • 5.7.Others
    • 5.7.1.Market size and forecast, by region
    • 5.7.2.Market analysis, by country

CHAPTER 6:LIVER DISEASE TREATMENT MARKET, BY REGION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.North America
    • 6.2.1.Key market trends, growth factors, and opportunities
    • 6.2.2.North America liver disease treatment market, by treatment type
    • 6.2.3.North America liver disease treatment market, by disease type
    • 6.2.4.Market size and forecast, by country
      • 6.2.4.1.U.S.
      • 6.2.4.1.1.U.S. liver disease treatment market, by treatment type
      • 6.2.4.1.2.U.S. liver disease treatment market, by disease type
      • 6.2.4.2.Canada
      • 6.2.4.2.1.Canada liver disease treatment market, by treatment type
      • 6.2.4.2.2.Canada liver disease treatment market, by disease type
      • 6.2.4.3.Mexico
      • 6.2.4.3.1.Mexico liver disease treatment market, by treatment type
      • 6.2.4.3.2.Mexico liver disease treatment market, by disease type
  • 6.3.Europe
    • 6.3.1.Key market trends, growth factors, and opportunities
    • 6.3.2.Europe liver disease treatment market, by treatment type
    • 6.3.3.Europe liver disease treatment market, by disease type
    • 6.3.4.Market size and forecast, by country
      • 6.3.4.1.Germany
      • 6.3.4.1.1.Germany liver disease treatment market, by treatment type
      • 6.3.4.1.2.Germany liver disease treatment market, by disease type
      • 6.3.4.2.France
      • 6.3.4.2.1.France liver disease treatment market, by treatment type
      • 6.3.4.2.2.France liver disease treatment market, by disease type
      • 6.3.4.3.UK
      • 6.3.4.3.1.UK liver disease treatment market, by treatment type
      • 6.3.4.3.2.UK liver disease treatment market, by disease type
      • 6.3.4.4.Italy
      • 6.3.4.4.1.Italy liver disease treatment market, by treatment type
      • 6.3.4.4.2.Italy liver disease treatment market, by disease type
      • 6.3.4.5.Spain
      • 6.3.4.5.1.Spain liver disease treatment market, by treatment type
      • 6.3.4.5.2.Spain liver disease treatment market, by disease type
      • 6.3.4.6.Rest of Europe
      • 6.3.4.6.1.Rest of Europe liver disease treatment market, by treatment type
      • 6.3.4.6.2.Rest of Europe liver disease treatment market, by disease type
  • 6.4.Asia-Pacific
    • 6.4.1.Key market trends, growth factors, and opportunities
    • 6.4.2.Asia-Pacific liver disease treatment market, by treatment type
    • 6.4.3.Asia-Pacific liver disease treatment market, by disease type
    • 6.4.4.Market size and forecast, by country
      • 6.4.4.1.Japan
      • 6.4.4.1.1.Japan liver disease treatment market, by treatment type
      • 6.4.4.1.2.Japan liver disease treatment market, by disease type
      • 6.4.4.2.China
      • 6.4.4.2.1.China liver disease treatment market, by treatment type
      • 6.4.4.2.2.China liver disease treatment market, by disease type
      • 6.4.4.3.Australia
      • 6.4.4.3.1.Australia liver disease treatment market, by treatment type
      • 6.4.4.3.2.Australia liver disease treatment market, by disease type
      • 6.4.4.4.India
      • 6.4.4.4.1.India liver disease treatment market, by treatment type
      • 6.4.4.4.2.India liver disease treatment market, by disease type
      • 6.4.4.5.South Korea
      • 6.4.4.5.1.South Korea liver disease treatment market, by treatment type
      • 6.4.4.5.2.South Korea liver disease treatment market, by disease type
      • 6.4.4.6.Rest of Asia-Pacific
      • 6.4.4.6.1.Rest of Asia-Pacific liver disease treatment market, by treatment type
      • 6.4.4.6.2.Rest of Asia-Pacific liver disease treatment market, by disease type
  • 6.5.LAMEA
    • 6.5.1.Key market trends, growth factors, and opportunities
    • 6.5.2.LAMEA liver disease treatment market, by treatment type
    • 6.5.3.LAMEA liver disease treatment market, by disease type
    • 6.5.4.LAMEA liver disease treatment market, by country
      • 6.5.4.1.Brazil
      • 6.5.4.1.1.Brazil liver disease treatment market, by treatment type
      • 6.5.4.1.2.Brazil liver disease treatment market, by disease type
      • 6.5.4.2.Saudi Arabia
      • 6.5.4.2.1.Saudi Arabia liver disease treatment market, by treatment type
      • 6.5.4.2.2.Saudi Arabia liver disease treatment market, by disease type
      • 6.5.4.3.South Africa
      • 6.5.4.3.1.South Africa liver disease treatment market, by treatment type
      • 6.5.4.3.2.South Africa liver disease treatment market, by disease type
      • 6.5.4.4.Rest of LAMEA
      • 6.5.4.4.1.Rest of LAMEA liver disease treatment market, by treatment type
      • 6.5.4.4.2.Rest of LAMEA liver disease treatment market, by disease type

CHAPTER 7:COMPANY PROFILES

  • 7.1.ABBVIE INC.
    • 7.1.1.Company overview
    • 7.1.2.Company snapshot
    • 7.1.3.Operating business segments
    • 7.1.4.Product portfolio
    • 7.1.5.Business performance
    • 7.1.6.Key strategic moves and developments
  • 7.2.ABBOTT LABORATORIES
    • 7.2.1.Company overview
    • 7.2.2.Company snapshot
    • 7.2.3.Operating business segments
    • 7.2.4.Product portfolio
    • 7.2.5.Business performance
  • 7.3.ASTELLAS PHARMA INC.
    • 7.3.1.Company overview
    • 7.3.2.Company snapshot
    • 7.3.3.Operating business segments
    • 7.3.4.Product portfolio
    • 7.3.5.Business performance
  • 7.4.BRISTOL-MYERS SQUIBB
    • 7.4.1.Company overview
    • 7.4.2.Company snapshot
    • 7.4.3.Operating business segments
    • 7.4.4.Product portfolio
    • 7.4.5.Business performance
  • 7.5.ELI LILLY AND COMPANY
    • 7.5.1.Company overview
    • 7.5.2.Company snapshot
    • 7.5.3.Operating business segments
    • 7.5.4.Product portfolio
    • 7.5.5.Business performance
    • 7.5.6.Key strategic moves and developments
  • 7.6.EMERGENT BIOSOLUTIONS INC. (CANGENE BIOPHARMA)
    • 7.6.1.Company overview
    • 7.6.2.Company snapshot
    • 7.6.3.Operating business segments
    • 7.6.4.Product portfolio
    • 7.6.5.Business performance
  • 7.7.F. HOFFMANN-LA ROCHE AG
    • 7.7.1.Company overview
    • 7.7.2.Company snapshot
    • 7.7.3.Operating business segments
    • 7.7.4.Product portfolio
    • 7.7.5.Business performance
    • 7.7.6.Key strategic moves and developments
  • 7.8.GILEAD SCIENCES, INC.
    • 7.8.1.Company overview
    • 7.8.2.Company snapshot
    • 7.8.3.Operating business segments
    • 7.8.4.Product portfolio
    • 7.8.5.Business performance
    • 7.8.6.Key strategic moves and developments
  • 7.9.MERCK & CO. INC.
    • 7.9.1.Company overview
    • 7.9.2.Company snapshot
    • 7.9.3.Operating business segments
    • 7.9.4.Product portfolio
    • 7.9.5.Business performance
    • 7.9.6.Key strategic moves and developments
  • 7.10.VIATRIS INC.
    • 7.10.1.Company overview
    • 7.10.2.Company snapshot
    • 7.10.3.Operating business segments
    • 7.10.4.Product portfolio
    • 7.10.5.Business performance
Back to Top
전화 문의
F A Q